Clinomics Inc. as a leading precision medicine company, has been introducing next generation diagnostics tools for personalized molecular diagnosis of cancer and next generation sequencing (NGS)-based analysis service including sensitive cancer panels in research community. The liquid biopsy platform, CD-PRIME™ is an optimized microfluidics platform for easy and fast enrichment of circulating tumor cells (CTCs) in a whole blood sample (<5 minutes/3ml). CD-PRIME™ also provides a definite advantage to investigate circulating tumor DNA (ctDNA) and CTC from a single tube simultaneously minimizing the loss of precious sample.Clinomics distributes molecular diagnosis products of lung cancer from AmoyDx and liquid biopsy platform from Fluxion Bio in collaboration with competitive global technology companies.
CD-PRIME™ platform provides highly efficient workflow of liquid biopsy on cancer, and is registered as class-1 medical device in FDA. The system also received a CE mark. CD-PRIME™ for CTC analysis performs easily automated protocol of CTC enrichment and staining.